who is not a good candidate for semaglutide Tirzepatide vs. Semaglutide: Which Weight Loss Medication Right You? Understanding semaglutide (GLP-1 RA): Are

More recently, sibutramine and rimonabant were approved in Europe, then removed from the market because of cardiovascular risk and psychiatric problems, respectively

In light of this, GLP-1 RAs provide a high potential of being incorporated into diabetic patients' treatment plans, similar to SGLT-2 inhibitors, as they decrease MACE by 14%, macroalbuminuria by 26%, and the risk of all-cause mortality by 12% [15,49]

doi: 10.2174/1381612822666160209152033 [DOI] [PubMed] [Google Scholar] 63.Ozcan U, Cao Q, Yilmaz E, et al

(STEP-1) Lincoff AM, et al

Diarrhea can occur as well, sometimes alternating with constipation as the body adjusts

This enhances insulin secretion, reduces liver glucose production, and slows gastric emptying, decreasing appetite and food intake